Argenx, Blueprint Medicines, Sarepta likely M&A targets – analyst (NASDAQ:ARGX)


Book about Myasthenia gravis and medication, injection, syringe and pills

Marcelo Ricardo Daros/iStock via Getty Images

Argenx (NASDAQ:ARGX) Blueprint Medicines (NASDAQ:BPMC) and Sarepta Therapeutics (NASDAQ:SRPT) are likely takeover targets in the biotech sector, according to a Wedbush analyst.

Year-to-date there have been over $70 billion announced acquisitions in the biotech space and for the entire year last

Source link

Leave A Reply

Your email address will not be published.